• Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1655 Ezetimibe <1 mg/mL 81 mg/mL 81 mg/mL
S2748 Anacetrapib (MK-0859) <1 mg/mL 127 mg/mL 127 mg/mL
S7953 ETC-1002 <1 mg/mL 68 mg/mL <1 mg/mL
S2119 Probucol <1 mg/mL 103 mg/mL 103 mg/mL
S9187 Phillygenin -1 mg/mL 74 mg/mL -1 mg/mL
Catalog No. Information Product Use Citations Product Validations


Ezetimibe is a potent, selective, cholesterol absorption inhibitor, used to lower cholesterol.


Anacetrapib (MK-0859)

Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.



ETC-1002,also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).



Probucol is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.



Phillygenin, a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.

Tags: LDL modulation | LDL modulator | LDL regulation| LDL review